Scholarlink

<p>Cell therapies, such as T cell immunotherapies, hold significant promise for treating complex diseases; however, their widespread adoption has been hindered by challenges related to monitoring cells during culture, which has affected their consistency, potency, and cost. Here, we present a compact, low-cost, label-free quantitative phase imaging (QPI) platform to enable continuous, non-destructive, in-line monitoring of T cell cultures within bioreactors. We further develop quantitative, image-based assays that accurately characterizes T cell culture viability and activation from over 50 independent donors-including therapeutically relevant CAR-T cells — while also preserving culture sterility and eliminating the need for disruptive sampling and endpoint assays. Our findings establish a QPI-pipeline for label-free, in-line cell monitoring and characterization which can significantly improve cell manufacturing processes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Label-free in-line characterization of immune cell culture using quantitative phase imaging

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月27日

查看全文
  • Caroline E. Serafini,
  • Viswanath Gorti,
  • Paloma Casteleiro Costa,
  • Aaron D. Silva Trenkle,
  • Bharat Kanwar,
  • Bryan Wang,
  • Brian Wicker,
  • Linda E. Kippner,
  • Isaac LeCompte,
  • Rui Qi Chen,
  • Benjamin Joffe,
  • Ye Li,
  • Annie C. Bowles-Welch,
  • Jing Li,
  • Christine E. Brown,
  • Gabriel A. Kwong,
  • Stephen Balakirsky,
  • Krishnendu Roy,
  • Francisco E. Robles

摘要

Cell therapies, such as T cell immunotherapies, hold significant promise for treating complex diseases; however, their widespread adoption has been hindered by challenges related to monitoring cells during culture, which has affected their consistency, potency, and cost. Here, we present a compact, low-cost, label-free quantitative phase imaging (QPI) platform to enable continuous, non-destructive, in-line monitoring of T cell cultures within bioreactors. We further develop quantitative, image-based assays that accurately characterizes T cell culture viability and activation from over 50 independent donors-including therapeutically relevant CAR-T cells — while also preserving culture sterility and eliminating the need for disruptive sampling and endpoint assays. Our findings establish a QPI-pipeline for label-free, in-line cell monitoring and characterization which can significantly improve cell manufacturing processes.